Search

everythinglearnresearchcommunity

for

Search:↓

Acknowledging the struggle of hair loss, discussing treatments like finasteride, minoxidil and RU58841, and providing support to those dealing with it.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

RU58841, combined with Dutasteride and topical Minoxidil, is helping users slow hair loss. Long-term users report positive results without significant side effects.

The user started using topical latanoprost and dutasteride, experiencing significant hair shedding and scalp itchiness, possibly due to an allergic reaction. They are considering stopping the treatment if the shedding is linked to an allergy.

The user maintained their hair over five years using finasteride and recently started using Rogaine to improve the front. They experienced no side effects and are satisfied with the results, considering the alternative of more significant hair loss.

A 49-year-old is using finasteride, minoxidil, tretinoin, and ketoconazole shampoo to combat advanced hair loss and hopes for enough regrowth to consider a hair transplant. Progress is slow, but some improvement is noted by others.

The conversation discusses hair loss treatments, specifically Verteporfin. Users also mention Minoxidil, finasteride, and RU58841.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.

The conversation is about someone experiencing hair regrowth using Minoxidil and Dutasteride, along with other treatments. They report their hairline is improving and their forehead appears smaller.

The user is seeking a topical minoxidil and finasteride combination without propylene glycol due to scalp irritation. They are looking for a supplier in the US.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

A 21-year-old man shared his 2.5-year experience with hair loss treatments, including 1mg Propecia (finasteride) nightly, 12.5% Minoxidil once daily, 2% Nizoral shampoo 2-4 times a week, and later 5% Minoxidil once daily. He experienced minor side effects like watery semen and itchy scalp, and while he's seen fluctuations in hair growth, he's generally happy with the results and is considering experimental treatments like CB-03-01 and RU58841.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

Treatment options for female alopecia androgenetica, discussing the availability of spironolactone online in The Netherlands and other potential treatments like finasteride, minoxidil and RU58841.

The user is using oral minoxidil, dutasteride, finasteride, and biotin for hair regrowth. They experience side effects like ED but are willing to continue for hair preservation.

Potential treatments for hair loss, including the use of minoxidil, finasteride, and RU58841.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

Liquid minoxidil makes hair sticky and stiff; users suggest oral minoxidil or minoxidil foam as alternatives. Applying minoxidil four hours before showering can help with absorption.

Eucapil, containing fluridil, is used for hair loss but has impractical packaging. Some users find it effective for maintenance, while others suggest alternatives like anageninc with pyrilutamide.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation discusses improvements to a platform and mentions hair loss treatments including Minoxidil, finasteride, RU58841, and melatonin. It also highlights the addition of features like Google login, reply by email, keyword extraction, and a term glossary for better understanding of hair-related terminologies.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.